吡貝地爾

吡貝地爾
臨床資料
AHFS/Drugs.com	國際藥品名稱
給藥途徑	口服
ATC碼	N04BC08 (WHO) ;
法律規範狀態
法律規範	歐：Rx-only; 處方藥（℞-only）;
藥物動力學數據
生物利用度	10%（1小時高峰）
血漿蛋白結合率	70–80%
藥物代謝	廣泛肝
生物半衰期	1.7至6.9小時
排泄途徑	腎（68%）和膽管（25%）
識別資訊
	IUPAC命名法 2-[4-(benzo[1,3]dioxol-5-ylmethyl)piperazin-1-yl]pyrimidine; ;
CAS號	3605-01-4
PubChem CID	4850;
IUPHAR/BPS	49;
ChemSpider	4684 ;
UNII	DO22K1PRDJ;
KEGG	D07305 ;
ChEMBL	ChEMBL1371770 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID9045188 ;
ECHA InfoCard	100.020.695
化學資訊
化學式	C16H18N4O2
摩爾質量	298.35 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4;
	InChI InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2 ; Key:OQDPVLVUJFGPGQ-UHFFFAOYSA-N ;

吡貝地爾（INN：piribedil）是一種抗帕金森病藥物和哌嗪衍生物，可作為D₂和D₃受體激動劑。它還具有α₂-腎上腺素受體拮抗劑特性。^[2]^[3]

參考資料

^ Active substance: piribedil (PDF). List of nationally authorised medicinal products. European Medicines Agency. 26 November 2020.
^ Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. The Journal of Pharmacology and Experimental Therapeutics. June 2001, 297 (3): 876–887 [2024-04-05]. PMID 11356907. （原始內容存檔於2019-12-14）.
^ Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. The Journal of Pharmacology and Experimental Therapeutics. April 2003, 305 (1): 338–346. PMID 12649387. S2CID 29234876. doi:10.1124/jpet.102.046383.